Focusing on clinical trials of atezolizumab, a common immunotherapy treatment for non-small-cell lung cancer (NSCLC), the researchers found improved responsiveness to the drug in those with a BMI.
from Top Lifestyle News- News18.com https://ift.tt/2QtUPse
from Top Lifestyle News- News18.com https://ift.tt/2QtUPse
Comments
Post a Comment